# Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib

> **NCT01844583** · PHASE1 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 55 (actual)

## Conditions studied

- Solid Tumors
- Lymphoma

## Interventions

- **DRUG:** Alisertib
- **DRUG:** Esomeprazole
- **DRUG:** Rifampin

## Key facts

- **NCT ID:** NCT01844583
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06-25
- **Primary completion:** 2014-08-04
- **Final completion:** 2016-09-06
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2019-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01844583

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01844583, "Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01844583. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*